Self-amplified chain-shattering cinnamaldehyde-based poly(thioacetal) boosts cancer chemo-immunotherapy
Source abstract
Abstract
The selective activation of stimuli-responsive polymers in the tumor microenvironment is a great concern to achieve intelligent cancer therapy, but most of them show inadequate response due to insufficient endogenous triggering agents. Herein, we rationally designed a reactive oxygen species (ROS)-responsive cinnamaldehyde (CA)-based poly(thioacetal), consisting of ROS-responsive thioacetal (TA) and ROS-generating agent CA, with self-amplified chain-shattering polymer degradation. The mechanism of self-amplified chain-shattering is that endogenous ROS as a triggering agent facilitates chain cleavage of TA with the release of CA, which in turn produces more ROS through mitochondrial dysfunction, resulting in an exponential polymer degradation cascade. The polymer can be further modified with anticancer drug doxorubicin (DOX) for cooperative amplification of oxidative stress and immunogenic cell death (ICD) of tumor cells, thereby boosting the effect of chemo-immunotherapy. The self-amplified chain-shattering polymer designed in this work holds great promise in developing stimuli-responsive polymers for efficient drug delivery. STATEMENT OF SIGNIFICANCE: This study presented an approach to utilize self-amplified chain-shattering cinnamaldehyde-based poly (thioacetal) as a drug delivery system to restrain tumor growth and boost chemo-immunotherapy. The endogenous ROS as a triggering agent initiates the chain cleavage with the release of CA, which in turn produces ROS through mitochondria dysfunction, resulting in an exponential polymer degradation cascade and rapid drug release.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery10.1038/nrd4333 ↗
2. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release10.1021/acs.chemrev.5b00346 ↗
3. Bioresponsive materials10.1038/natrevmats.2016.75 ↗
4. Stimuli-responsive prodrug-based cancer nanomedicine10.1016/j.ebiom.2020.102821 ↗
5. Peptide-based multifunctional nanomaterials for tumor imaging and therapy10.1002/adfm.201804492 ↗
6. Localized delivery of active targeting micelles from nanofibers patch for effective breast cancer therapy10.1016/j.ijpharm.2020.119412 ↗
7. Progress and challenges towards targeted delivery of cancer therapeutics10.1038/s41467-018-03705-y ↗
8. Time-programmed activation of dual polyprodrugs for synergistic cascade oxidation-chemotherapy10.1016/j.biomaterials.2021.121136 ↗
9. Sericin/RBA embedded gellan gum based smart nanosystem for pH responsive drug delivery10.1016/j.ijbiomac.2018.09.146 ↗
10. Enzyme-instructed activation of pro-protein therapeutics in vivo10.1021/jacs.9b08669 ↗
11. Effective and selective anti-cancer protein delivery via all-functions-in-one nanocarriers coupled with visible light-responsive, reversible protein engineering10.1002/adfm.201706710 ↗
12. A boronic acid conjugate of angiogenin that shows ROS-responsive neuroprotective activity10.1002/anie.201611446 ↗
13. Continuous head-to-tail depolymerization: an emerging concept for imparting amplified responses to stimuli-responsive materials10.1021/mz5000784 ↗
14. Stimuli-responsive nanomaterials for biomedical applications10.1021/ja510147n ↗
15. Programmable microcapsules from self-immolative polymers10.1021/ja104812p ↗
16. Amplified release through the stimulus triggered degradation of self-immolative oligomers, dendrimers, and linear polymers10.1016/j.addr.2011.09.012 ↗
17. Chain-shattering polymeric therapeutics with on-demand drug-release capability10.1002/anie.201300497 ↗
18. Hyperbranched self-immolative polymers (hSIPs) for programmed payload delivery and ultrasensitive detection10.1021/jacs.5b05060 ↗
19. Dendritic, oligomeric, and polymeric self-immolative molecular amplification10.1021/acs.chemrev.5b00372 ↗
20. Activity-based optical sensing enabled by self-lmmolative Scaffolds: monitoring of release events by fluorescence or chemiluminescence output10.1021/acs.accounts.9b00338 ↗
21. Sensing through signal amplification10.1039/c1cs15024c ↗
22. Approaches towards molecular amplification for sensing10.1039/C6AN00348F ↗
23. Chemical amplification resists: Inception, implementation in device manufacture, and new developments10.1002/pola.10963 ↗
24. Coordinating external and built-in triggers for tunable degradation of polymeric nanoparticles via cycle amplification10.1021/jacs.1c05617 ↗
25. Mitochondria, oxidants, and aging10.1016/j.cell.2005.02.001 ↗
26. A reactive oxygen species (ROS)-responsive polymer for safe, efficient, and targeted gene delivery in cancer cells10.1002/anie.201209633 ↗
27. ROS-Responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy10.1002/adma.201700141 ↗
28. Exploiting oxidative microenvironments in the body as triggers for drug delivery systems10.1089/ars.2013.5754 ↗
29. Dual pH/ROS-responsive nanoplatform with deep tumor penetration and self-amplified drug release for enhancing tumor chemotherapeutic efficacy10.1002/smll.202002188 ↗
30. Lysosome-targeting amplifiers of reactive oxygen species as anticancer prodrugs10.1002/anie.201706585 ↗
31. Hybrid nanoreactors: enabling an off-the-shelf strategy for concurrently enhanced chemo-immunotherapy10.1002/anie.201807595 ↗
32. Transformable honeycomb-like nanoassemblies of carbon dots for regulated multisite delivery and enhanced antitumor chemoimmunotherapy10.1002/anie.202014397 ↗
33. Rationally designed polymer conjugate for tumor-specific amplification of oxidative stress and boosting antitumor immunity10.1021/acs.nanolett.9b05265 ↗
34. Inducing endoplasmic reticulum stress to expose immunogens: a DNA tetrahedron nanoregulator for enhanced immunotherapy10.1002/adfm.202000532 ↗
35. Self-amplified drug delivery with light-inducible nanocargoes to enhance cancer immunotherapy10.1002/adma.201902960 ↗
36. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma10.1021/acsnano.0c00708 ↗
37. Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer10.1016/j.nantod.2020.101025 ↗
38. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses10.1126/sciadv.aaz4204 ↗
39. Tumor-acidity and bioorthogonal chemistry-mediated on-site size transformation clustered nanosystem to overcome hypoxic resistance and enhance chemoimmunotherapy10.1021/acsnano.1c08232 ↗
40. Smart nanosized drug delivery systems inducing immunogenic cell death for combination with cancer immunotherapy10.1021/acs.accounts.0c00254 ↗
41. Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells10.1016/S0304-3835(03)00238-6 ↗
42. Apoptosis induction of 2′-hydroxycinnamaldehyde as a proteasome inhibitor is associated with ER stress and mitochondrial perturbation in cancer cells10.1016/j.bcp.2007.05.016 ↗
43. dual acid-responsive micelle-forming anticancer polymers as new anticancer therapeutics10.1002/adfm201300871 ↗
44. Carbon-dot-supported atomically dispersed gold as a mitochondrial oxidative stress amplifier for cancer treatment10.1038/s41565-019-0373-6 ↗
45. Light-activatable red blood cell membrane-camouflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy10.1021/acsnano.7b08219 ↗
46. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap10.1038/s41467-018-04605-x ↗
47. Immunogenic cell death in cancer and infectious disease10.1038/nri.2016.107 ↗
48. Synthetic immunogenic cell death mediated by intracellular delivery of STING agonist nanoshells enhances anticancer chemo-immunotherapy10.1021/acs.nanolett.9b04094 ↗
49. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity10.1038/ncomms15618 ↗
50. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells10.1126/scitranslmed.3006504 ↗
51. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases10.1038/nature02238 ↗